Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
77.45
+0.69 (0.90%)
Aug 10, 2026, 3:38 PM EDT - Market open
Cytokinetics Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 67.67 | 88.04 | 18.47 | 7.53 | 94.59 | 70.43 |
Revenue Growth | -21.07% | 376.56% | 145.34% | -92.04% | 34.30% | 26.15% |
Gross Profit Gross Profit Growth | 59.53 | 88.04 | 18.47 | 7.53 | 94.59 | 70.43 |
Operating Income Operating Income Growth | -707.91 | -612.26 | -536.25 | -496.21 | -324.2 | -186.31 |
Net Income Net Income Growth | -894 | -784.96 | -589.53 | -526.24 | -388.96 | -215.31 |
Earnings Per Share EPS Growth | -7.22 | -6.54 | -5.26 | -5.45 | -4.33 | -2.80 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Research and Development Research and Development Growth | 10.62 | 8.69 | 3.47 | 4.03 | 6.59 | 10.57 |
Milestone Milestone Growth | - | 79.35 | 15 | 3.5 | 1 | 5 |
Revenue (Total) Revenue (Total) Growth | 67.67 | 88.04 | 18.47 | 7.53 | 94.59 | 70.43 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 1,166 | 882.22 | 1,076 | 614.82 | 782.58 | 471.64 |
Total Debt Total Debt Growth | 1,271 | 1,284 | 788.68 | 755.77 | 750.3 | 269.93 |
Net Cash (Debt) Net Cash Growth | -104.87 | -402.02 | 287.34 | -140.95 | 32.28 | 201.71 |
Net Cash Growth | - | - | - | - | -84.00% | -37.96% |
Net Cash Per Share Net Cash Per Share Growth | -0.84 | -3.35 | 2.57 | -1.46 | 0.36 | 2.62 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -555.45 | -510.01 | -395.89 | -414.33 | -299.52 | -142.52 |
Capital Expenditures CapEx Growth | -25.26 | -24.81 | -3.91 | -1.42 | -11.34 | -48.87 |
Free Cash Flow Free Cash Flow Growth | -580.72 | -534.82 | -399.8 | -415.75 | -310.85 | -191.39 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 87.97% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | -1046.12% | -695.44% | -2902.72% | -6589.71% | -342.75% | -264.54% |
Pretax Margin | -1104.07% | -891.60% | -3191.11% | -6988.63% | -411.21% | -305.72% |
Profit Margin | -1321.12% | -891.60% | -3191.11% | -6988.63% | -411.21% | -305.72% |
FCF Margin | -858.16% | -607.48% | -2164.10% | -5521.24% | -328.64% | -271.76% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PS Ratio | 158.13 | 88.73 | 300.99 | 1126.93 | 45.94 | 54.88 |